Global Leading Market Research Publisher QYResearch Announces the Release of Its Latest Report: “Bioprocess Infusion Bags – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”
The biopharmaceutical manufacturing sector is undergoing a transformative phase, propelled by advances in continuous cell culture, high-density perfusion processes, and single-use technologies. QYResearch introduces its latest report, “Bioprocess Infusion Bags – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”, offering an in-depth evaluation of market dynamics, size, share, industry trends, and growth projections. Designed to inform CEOs, market strategists, investors, and manufacturing executives, this report equips decision-makers with actionable insights to navigate the expanding single-use bioprocessing ecosystem.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6117149/bioprocess-infusion-bags
Market Overview
The global market for bioprocess infusion bags was valued at US$ 2,178 million in 2025 and is projected to reach US$ 3,618 million by 2032, corresponding to a CAGR of 7.6% over the forecast period. In 2024, global sales reached approximately 4.72 million units, with an average selling price of US$ 6 per unit.
Bioprocess infusion bags are pre-sterilized, ready-to-use containers that incorporate 0.2–0.65 µm hollow fiber or sheet-like microporous membranes. These bags facilitate continuous perfusion processes, allowing fresh culture medium to be added while simultaneously draining waste and products, thereby achieving high cell density and elevated product yields.
Product Definition and Functional Benefits
Bioprocess infusion bags are a cornerstone of modern single-use biomanufacturing, supporting processes in cell therapy, vaccine production, and monoclonal antibody (MAB) or recombinant protein manufacturing. Key features include:
- Integrated Membranes: Hollow fiber membranes made from polysulfone (PSU) or polyethersulfone (PES) enable efficient nutrient delivery and metabolite removal
- Sterility and Safety: Bags are gamma-ray sterilized, maintaining aseptic conditions for critical cell culture processes
- Versatility: Available in 2D and 3D configurations, accommodating different bioreactor geometries and process requirements
- Enhanced Productivity: Continuous perfusion technology supports high cell density cultures and optimal product yield, significantly reducing downtime and labor costs
Cost Structure Insights: Hollow fiber membranes account for 38–42% of the unit cost, while bag assembly, welding, and labor contribute 15%. Sterilization and integrity testing account for 8%, and validation and release documentation add 6%. The remaining 29–33% covers gross profit, distribution, and after-sales services. Domestic production of hollow fiber membranes can reduce material costs by 35%, lowering overall production costs by roughly 22%, which explains why domestic infusion bags can be priced at one-third of imported equivalents.
Industry Value Chain
The bioprocess infusion bag industry operates across three primary segments: upstream materials, midstream manufacturing, and downstream bioprocess applications.
1. Upstream:
- Sourcing of high-performance hollow fiber membranes (PSU, PES), multilayer co-extruded films, and other barrier materials
- Quality control testing and compliance with ISO and cGMP standards
- Sterilization technologies and membrane validation for continuous perfusion performance
2. Midstream:
- Device manufacturers and CDMOs/CMOs perform bag assembly, welding, membrane integration, and sterilization
- Development of pre-configured 2D or 3D bag systems compatible with existing perfusion bioreactors
- Continuous R&D on perfusion efficiency, membrane longevity, and aseptic handling
3. Downstream:
- Biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions
- Key applications include cell therapy, vaccine manufacturing, MAB, and recombinant proteins
- Distribution channels include specialty suppliers, biotech logistics providers, and direct-to-factory solutions
Market Drivers
1. Rising Demand for High-Yield Bioprocessing:
- Continuous perfusion processes enable higher cell densities and product titers, reducing manufacturing costs per gram of biologics
- Biologics and advanced therapies are driving demand for efficient, single-use infusion systems
2. Expansion of Single-Use Technology Adoption:
- Single-use bioprocessing offers reduced contamination risk, flexibility, and lower capital investment
- Infusion bags are critical for adapting perfusion technologies at small and large scales
3. Advancements in Cell Therapy and Vaccines:
- Increasing cell therapy trials and commercial launches necessitate reliable infusion systems
- Vaccines, including mRNA and viral vector platforms, benefit from sterile perfusion bags for optimized cell culture
4. Cost Reduction via Domestic Manufacturing:
- Local production of membranes and films reduces import dependency, lowers unit costs, and enhances market penetration in cost-sensitive regions
Market Challenges
While opportunities abound, several challenges may affect growth:
- High reliance on imported membranes in certain markets impacts cost competitiveness
- Technical complexity of continuous perfusion and membrane handling requires skilled operators
- Regulatory compliance and validation processes increase time-to-market and development costs
- Emerging competitors offering innovative membrane technologies may intensify price competition
Strategically, companies that focus on domestic membrane sourcing, integrated perfusion systems, and global regulatory compliance will maintain market leadership.
Market Segmentation
By Type:
- 2D Bags: Flat sheet configurations suitable for small- to medium-scale perfusion bioreactors
- 3D Bags: Volumetric designs enabling optimized mixing and enhanced surface area for high-density cultures
By Application:
- Cell Therapy: Critical for therapeutic cell expansion and processing
- Vaccine Production: Supports scalable vaccine manufacturing platforms
- MAB and Recombinant Proteins: Facilitates high-titer monoclonal antibody and protein production
- Others: Emerging biopharmaceutical applications, research, and experimental platforms
Key Market Players
The global infusion bag market is competitive and diversified, including major multinational suppliers and emerging regional manufacturers:
- Sartorius
- Merck
- Thermo Fisher Scientific
- Danaher
- Avantor
- Corning
- Entegris
- LePure Biotech
- Saint Gobain
- SATAKE MultiMix
- Zhejiang JYSS Bio-Engineering
- Tofflon
- Duoning Biotech
- ABEC
- AUSTAR Group
These players leverage product innovation, membrane technology, quality assurance, and global distribution networks to strengthen their positions and meet the growing demand for perfusion-based bioprocessing.
Future Outlook
The bioprocess infusion bag market is set to continue strong growth through 2032, driven by:
- Rising adoption of continuous perfusion processes and single-use technologies
- Ongoing innovation in hollow fiber membranes and bag design
- Expansion in cell therapy, vaccine, and biologics production
- Increasing domestic production capacity, reducing reliance on imports, and enabling price-competitive solutions
Strategic Recommendations:
- Manufacturers should prioritize membrane sourcing, production efficiency, and regulatory compliance
- Companies offering turnkey perfusion bag systems that integrate with bioreactors and automation solutions will differentiate themselves in the market
- Investors and CEOs should monitor adoption trends in emerging markets and regulatory pathways to maximize ROI
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
